Cigna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as not medically necessary by Cigna?

Q: How long do I have to appeal a Cigna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Most insurers reverse a medical-necessity denial when the appeal cites the specific clinical guideline (NCCN, ADA, AACE, etc.) that supports the requested treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

T2DM diagnosis required (CNF-749); HbA1c ≥6.5% consistent with ADA.

Source policy: Cigna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Cigna angle on Tirzepatide

## Cigna Medical-Necessity Denials for Tirzepatide: The Coverage Position Bulletin 749 Mechanic

When Cigna issues a medical-necessity denial for tirzepatide (Mounjaro/Zepbound), the denial is almost never a clinical disagreement — it is a Coverage Position Number (CNF) 749 documentation gate failure. Cigna's pharmacy benefit, administered through Express Scripts/Evernorth/Accredo, applies CNF-749 as the controlling utilization management document: T2DM diagnosis confirmation via ICD-10 E11.x, a baseline HbA1c ≥6.5% consistent with ADA Standards of Care §2, and metformin trial documentation (or contraindication). Denials citing "medical necessity not established" typically reflect a missing HbA1c lab value within the lookback window or a chart note that lists "T2DM" without the corresponding lab confirmation Cigna's clinical reviewers require.

The procedural error most appellants make is routing the appeal through the medical benefit. Tirzepatide for T2DM is adjudicated through Express Scripts, not Cigna's medical UM team. Appeals submitted to the medical address get re-routed, blowing the 72-hour expedited / 30-day standard clock under 29 CFR §2560.503-1(f). File directly with Express Scripts' Prior Authorization Appeals unit (fax 877-328-9660) and reference CNF-749 by name in the first paragraph.

ERISA disclosure rights are the lever here. Under 29 CFR §2560.503-1(h)(2)(iii), Cigna must produce the specific clinical rationale, the internal rule applied, and the qualifications of the reviewer on request. Send a written §503-1(m)(8) demand for: (1) the full CNF-749 version in effect on the denial date, (2) the clinical reviewer's board certification, and (3) any internal guideline used beyond the published bulletin. Cigna's CNF documents are revised quarterly; citing the wrong version is grounds for remand. If the plan is fully-insured, file a parallel complaint with the state DOI — particularly effective in CA, NY, TX, and WA, where market conduct exams have flagged Cigna's GLP-1 UM pattern.

For the clinical rebuttal, attach: the most recent HbA1c with collection date inside 90 days of the PA request, a problem-list note explicitly stating Type 2 diabetes (not "diabetes NOS"), and the metformin failure/intolerance documentation. If the patient was step-edited off semaglutide, cite 29 USC §1185d (step-therapy override) and document the adverse reaction or therapeutic failure with dated chart entries. Pinto v. Aetna, 740 F.3d 1037 (10th Cir. 2014), squarely places the burden of proving experimental/non-necessity on the plan once the treating physician documents medical judgment — Cigna cannot rely on a conclusory "not medically necessary" letter.

Tactical closer: Request a peer-to-peer with a board-certified endocrinologist, not an internist. Cigna's default reviewer pool skews to family medicine; demanding specialty-matched review under CNF-749's own "qualified reviewer" language frequently flips the denial at first-level appeal.

## TL;DR

Cigna medical-necessity denials for tirzepatide are CNF-749 documentation failures. Appeal through Express Scripts, demand the exact CNF version under ERISA §503-1(h), attach HbA1c ≥6.5% with an E11.x diagnosis, and request specialty-matched peer review.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other insurers on Tirzepatide

Other denial reasons for Cigna Tirzepatide

denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.